✦ LIBER ✦

Incidence of developmental defects at the no observed adverse effect level (NOAEL)

✍ Scribed by David W. Gaylor

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Assessment of the no-observed-adverse-ef

✍ K Rajalakshmi; H Devaraj; S Niranjali Devaraj 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 271 KB

Determination of an Acute No-Observed-Ad

✍ Magdalena Araya; Marie Clare McGoldrick; Leslie M. Klevay; J.J. Strain; Paula Ro 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 95 KB

The No Observed Adverse Effect Level (NO

✍ Kim, Hyung-Sik; Um, Yoon-Mi; Shin, Min-Kyung; Park, Hyun-Jong; Lee, Jung-Dae; Ki 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 63 KB

Effect of chronic T-2 toxin exposure in

✍ Kovács, Melinda; Tornyos, Gábor; Matics, Zsolt; Mézes, Miklós; Balogh, Krisztián 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 363 KB

Comparison of benchmark doses (BMD) with

✍ Nair, R.S.; Martens, M.A. 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 128 KB

Developmental toxicity of carbendazim: c

✍ A Mantovani; F Maranghi; C Ricciardi; C MacRi; A.V Stazi; L Attias; G.A Zapponi 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 794 KB